Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future Mulder K; Koski S; Scarfe A; Chu Q; King K; Spratlin JOncotarget 2010[Nov]; 1 (7): 515-29Advanced gastrointestinal (GI) malignancies are varied in presentation, prognosis, and treatment options. With the exception of resectable recurrent colorectal cancer, metastatic GI malignancies are incurable. Cytotoxic chemotherapies have been the mainstay of therapy for decades but limited extension of survival or clinical benefit has been achieved in non-colorectal GI cancers. There has been great interest in the incorporation of antiangiogenic strategies to improve outcomes for these patients. Clear benefits have been identified with bevacizumab and sorafenib in colorectal cancer and hepatocellular cancer, respectively; other GI tumor sites have lacked impressive results with antiangiogenic agents. In this review, we will present the benefits, or lack thereof, of clinically tested antiangiogenic compounds in GI malignancies and explore some potential new therapeutic anti-angiogenesis options for these diseases.|Adenocarcinoma/drug therapy/pathology[MESH]|Angiogenesis Inhibitors/*therapeutic use[MESH]|Biliary Tract Neoplasms/drug therapy/pathology[MESH]|Carcinoma/*drug therapy/pathology[MESH]|Disease Progression[MESH]|Drugs, Investigational/therapeutic use[MESH]|Gastrointestinal Neoplasms/*drug therapy/pathology[MESH]|Humans[MESH]|Liver Neoplasms/drug therapy/pathology[MESH]|Medical Oncology/methods/*trends[MESH]|Models, Biological[MESH]|Pancreatic Neoplasms/drug therapy/pathology[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH] |